Reta evidence library

Reta peptide research library

Research guides explaining what reta means, how retatrutide engages GLP-1, GIP and glucagon receptors, what published trials report, and how batch-level COA evidence should be verified. Comparisons are sourced and clearly separated from laboratory batch records.

For in-vitro laboratory research only. Not for human or veterinary use.

Articles

New ยท evidence tracker Retatrutide Phase 3 evidence Peer-reviewed TRANSCEND-T2D-1 findings, TRIUMPH sponsor topline results, trial records, and publication status. Evidence tracker Orforglipron Phase 3 evidence ATTAIN obesity and ACHIEVE type-2-diabetes Phase 3 results (peer-reviewed and sponsor topline), trial records, and the US obesity approval. Evidence tracker CagriSema Phase 3 evidence REDEFINE and REIMAGINE Phase 3 results โ€” including the REDEFINE 4 miss versus tirzepatide โ€” with trial records and publication status. Evidence tracker Survodutide Phase 3 evidence SYNCHRONIZE obesity and MASLD Phase 3 results, peer-reviewed Phase 2 MASH and obesity data, and pending liver and cardiovascular trials. Evidence tracker VK2735 Phase 2/3 evidence Peer-reviewed subcutaneous VENTURE Phase 2, the oral VENTURE topline, and the pending VANQUISH Phase 3 program โ€” subcutaneous and oral kept separate. Keyword guide Reta Peptide What is reta, what is reta peptide, how does reta work, and what does reta do in research studies. Comparison Reta vs Tirzepatide Receptor design, sourced trial readouts, half-life and the limits of indirect comparison. Landscape Next-Generation Incretin Pipeline 2026 Retatrutide, CagriSema, survodutide and orforglipron compared by molecular class, receptor design, regulatory stage and primary-source readouts. Regulatory landscape Compounded GLP-1s in 2026 Post-shortage state of US semaglutide and tirzepatide compounding: wind-down deadlines, the April 2026 FDA 503B proposal, enforcement actions, adverse-event data, and where retatrutide sits.